ARYA Sciences Acquisition Corp IV focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: perceptivelife.com/arya4
| Date | Price Target | Rating | Analyst |
|---|
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
4 - ARYA Sciences Acquisition Corp IV (0001838821) (Issuer)
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company"))), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug Administration ("FDA") approval for the FULCRUM-VT Pivotal IDE study Cl
Business combination transaction with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by an affiliate of Perceptive Advisors, closed on July 31, 2024 Publicly traded company renamed Adagio Medical Holdings, Inc., with Adagio Medical as an operating subsidiary Common stock expected to commence trading under ticker symbol "ADGM" on the Nasdaq Capital Market on August 1, 2024 Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, announced today the completion of its business combination with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD, or "ARYA IV"))), a special purpos
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
Combined Company expects to receive approximately $42 million from equity and convertible note investors at closing. LAGUNA HILLS, Calif., Feb. 14, 2024 /PRNewswire/ -- Adagio Medical, Inc. ("Adagio Medical"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, and ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) ("ARYA"), a special purpose acquisition company that is sponsored by an affiliate of Perceptive Advisors, LLC ("Perceptive Advisors"), today announced they have entered a definitive agreement (the "business combination agreement") for a business combination (the "transaction"). Upon closing of the transaction, Adagio Medical will become a subsi
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) ("ARYA IV"), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (NASDAQ:FOLD) ("Amicus") to terminate their previously announced Business Combination Agreement (the "Business Combination Agreement"), effective immediately. "While this is not the outcome we had hoped for, ARYA IV still has over a year remaining to identify and execute on a business combination transaction and the ARYA IV team believes it is well positioned to identify and execute on an
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Global Commercialization and Late Stage Product Development Biotechnology Company in Rare Diseases Transaction Advances Amicus Path to Profitability - Expected as of 2023 Amicus Balance Sheet Further Strengthened with a ~$200M Private Investment from Leading Biotechnology Investors Separation will Sharpen the Strategic Focus, Financial Profile, and Operational Execution of Both Companies to Address the Needs of People Living with Rare Diseases – A
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
SC 13G/A - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and
The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "ADGM". Investors have committed to participate in the transaction in the form of $20 million in convertible debt and $22 million in equity financing.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1838821/000114036123016524/brhc10050928_8k.htm
During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was Dell Technologies (NYSE:DELL). The smallest company on a market cap basis to set a new 52-week low was Dynatronics (NASDAQ:DYNT). Everbridge (NASDAQ:EVBG)'s stock came under the most pressure, trading down 39.63% to reach a new 52-week low. Blue Ocean Acquisition (NASDAQ:BOCN) shares were the most resilient, as shares rose 0.1%, rebounding from its new 52-week low. Check out this: Insiders Buy Around $98M Of 3 Stocks These stocks set new 52-week lows on Friday: Opendoor Technologies (NASDAQ:OPEN) shares reac
Amicus Therapeutics Inc (NASDAQ:FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market conditions" sinking the planned merger with ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD), Amicus plans to prioritize its gene therapy pipeline as part of a push to generate $400 million in net savings through 2026. By merging its gene therapy unit with Perceptive Advisors' ARYA Sciences Acquisition Corp IV, Amicus planned to reduce its outgoings and step up its push for profitability. The deal would have given Amicus a chance to profit from the success of the spinout via a 36% stake in the Company but free it from the cost of developin
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ:ADGI) announced that its board has appointed David Hering as interim chief executive officer, effective immediately. Hering's appointment came following the resignation of Tillman Gerngross as CEO. The interim CEO will retain his role as chief operating officer. Adagio also said It has initiated a formal CEO search and plan to appoint an executive with proven experience in bringing products to market and scaling operations. Orphazyme Says EMA Committee Leaning Against Approval Of Arimoclomol Orphazyme A/S (N
ARYA Sciences Acquisition Corp IV (NASDAQ:ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (NASDAQ:FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately. “While this is not the outcome we had hoped for, ARYA IV still has over a year remaining to identify and execute on a business combination transaction and the ARYA IV team believes it is well positioned to identify and execute on an opportunity that meets its key investment crit
15-12G - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
25-NSE - ARYA Sciences Acquisition Corp IV (0001838821) (Subject)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
DEFM14A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
8-K - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)
10-Q/A - ARYA Sciences Acquisition Corp IV (0001838821) (Filer)